• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

PILA PHARMA

1.32 SEK

-0.75 %

Less than 1K followers

PILA

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Compare
-0.75 %
-20.06 %
+10.69 %
-36.17 %
-38.55 %
-57.21 %
-38.06 %
-
-83.17 %

PILA PHARMA is a clinical stage biotechnology company based in Malmö, Sweden. The company is developing novel oral therapeutics for globally common metabolic diseases such as Diabetes, Obesity and Cardiovascular diseases as well as therapeutics for Pain treatment. The company has obtained an orphan drug designation in the United States for the rare disease Erythromelalgia. The company is specializing in development of pharmaceutical drugs based on TRPV1-antagonists.

Read more
Market cap
60.07M SEK
Turnover
39.76K SEK
Revenue
1.13M
EBIT %
-698.23 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
27/8
2026

Interim report Q2'26

25/2
2027

Annual report '26

All
Webcasts
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Press release6/3/2026, 11:50 AM

Carlsquare: Equity reseach Pila Pharma: Sizing up a small molecule in obesity

PILA PHARMA
Regulatory press release5/19/2026, 4:00 PM

REPORT FROM PILA PHARMA AB’S ANNUAL GENERAL MEETING 2026

PILA PHARMA
Regulatory press release5/19/2026, 4:00 PM

KOMMUNIKÉ FRÅN PILA PHARMA’S ÅRSSTÄMMA 2026

PILA PHARMA

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/6/2026, 7:30 AM

PILA PHARMA: UPCOMING INVESTOR EVENTS AND INTERVIEWS - PRESENTING AT REDEYE DIABETES DAY ON 06 MAY

PILA PHARMA
Press release4/28/2026, 10:15 AM

BioStock: Pila Pharma om de prekliniska resultaten och vägen framåt

PILA PHARMA
Press release4/28/2026, 10:15 AM

BioStock: Pila Pharma on the preclinical results and the way forward

PILA PHARMA
Regulatory press release4/21/2026, 6:50 AM

PILA PHARMA PUBLISHES ITS ANNUAL REPORT FOR 2025

PILA PHARMA
Press release4/17/2026, 8:00 AM

Vækstaktier.dk: PILA PHARMA clarified: Poor formulation led to low exposure – plausible explanation for lack of effect on body weight

PILA PHARMA
Press release4/17/2026, 7:58 AM

BioStock: Rättelse: Analys bekräftar att Pila Pharmas prekliniska resultat förklaras sannolikt av låg läkemedelsexponering

PILA PHARMA
Press release4/17/2026, 7:58 AM

BioStock: Correction: Pila Pharma’s unanticipated obesity results plausibly explained by low drug exposure, analyses confirms

PILA PHARMA
Press release4/17/2026, 7:05 AM

Analyst Group: Analyst Group Comments on Pila Pharma’s Confirmation That Low Exposure of XEN-D0501 Plausibly Resulted in the Absence of Effects in Preclinical Obesity Studies

PILA PHARMA
Press release4/17/2026, 7:05 AM

Analyst Group: Analyst Group kommenterar Pila Pharmas bekräftelse om att låg exponering av XEN-D0501 sannolikt resulterade i avsaknad av effekt i prekliniska obesitasstudier

PILA PHARMA
Press release4/17/2026, 6:34 AM

BioStock: Pila Pharmas prekliniska resultat förklaras sannolikt av låg läkemedelsexponering

PILA PHARMA
Press release4/17/2026, 6:34 AM

BioStock: Pila Pharmas preclinical results plausibly explained by low drug exposure

PILA PHARMA
Regulatory press release4/16/2026, 12:15 PM

PILA PHARMA: UPDATE TO PRECLINICAL RAT OBESITY STUDIES - LOW EXPOSURE OF XEN-D0501 COULD EXPLAIN LACK OF EFFECT ON BODYWEIGHT

PILA PHARMA
Regulatory press release4/16/2026, 6:40 AM

KALLELSE TILL ÅRSSTÄMMA I PILA PHARMA AB

PILA PHARMA
Press release3/25/2026, 2:08 PM

BioStock: Pila Pharma uppdaterar från Bio-Europe Spring i Lissabon

PILA PHARMA
Press release3/25/2026, 2:08 PM

BioStock: Pila Pharma updates from Bio-Europe Spring in Lisbon

PILA PHARMA
Press release3/19/2026, 4:00 PM

PILA PHARMA CLARIFIES: DECISION TO POSTPONE THE ANNUAL REPORT TO AWAIT CONCLUSION ON PRECLINICAL OBESITY STUDIES

PILA PHARMA
Regulatory press release3/18/2026, 5:15 PM

PILA PHARMA POSTPONES THE PUBLICATION OF THE ANNUAL REPORT AND THE ANNUAL GENERAL MEETING

PILA PHARMA